Guidelines for Screening and Treating Benign Prostatic Hyperplasia (BPH)

Initial Diagnostic Evaluation

• The American Urological Association (AUA) recommends a systematic approach to BPH screening that includes medical history, symptom assessment using the AUA Symptom Index, physical examination including digital rectal examination, urinalysis, and selective PSA testing for men with at least a 10-year life expectancy 1, 2, 3
• Medical History: Obtain detailed history of urinary symptoms, previous surgeries, medical conditions, medications, and family history of prostate disease (BPH and cancer) 1
• Symptom Assessment: The AUA Symptom Index (identical to the International Prostate Symptom Score [IPSS]) should be used to quantify symptom severity (mild: 0-7, moderate: 8-19, severe: 20-35) 4
• Physical Examination: A digital rectal examination (DRE) and focused neurologic examination are mandatory to assess prostate size and exclude locally advanced prostate cancer 3, 5
• Urinalysis: Perform dipstick testing or microscopic examination to screen for hematuria and urinary tract infection 3
• PSA Testing: Should be offered to patients with at least a 10-year life expectancy for whom knowledge of prostate cancer would change management, or when PSA measurement may influence voiding symptom management 3, 5

Optional Diagnostic Tests

• Urine Cytology: Consider in men with predominantly irritative symptoms, especially those with smoking history or other risk factors for bladder cancer 2, 3
• Pressure-Flow Studies: Optional before invasive therapy, particularly for men with flow rates >10 mL/sec when surgery is being considered, or in those with neurological conditions affecting bladder function 6, 7
• Urethrocystoscopy: Appropriate for men with history of hematuria, urethral stricture, bladder cancer, or prior lower urinary tract surgery 6
• Prostate Ultrasound: May be appropriate when minimally invasive or surgical interventions are chosen, but not routinely necessary for watchful waiting or medical therapy 6, 7

Not Recommended Tests

• Serum Creatinine: Routine measurement is not indicated in initial evaluation as baseline renal insufficiency is no more common in men with BPH than in the general population 4, 5
• Upper Urinary Tract Imaging: Not recommended unless the patient has hematuria, UTI, renal insufficiency, or history of urolithiasis or urinary tract surgery 6

Treatment Algorithm Based on Symptom Severity

• Surgical Options: Consider transurethral resection of the prostate (TURP) or other surgical interventions for severe symptoms (AUA Score 20-35) 6

Common Pitfalls and Caveats

• PSA levels can be affected by BPH; approximately 25% of men with BPH have PSA >4 ng/mL 3

Diagnostic Approach for Benign Prostatic Hyperplasia

Mandatory Initial Evaluation

• The American Urological Association recommends including the disease-specific quality of life question from the IPSS to assess how bothersome symptoms are to the patient, as intervention may be more appropriate for a moderately symptomatic patient who finds symptoms bothersome than for a severely symptomatic patient who tolerates them 8
• Consider additional validated instruments like the BPH Impact Index to measure interference with daily activities, as suggested by The Journal of Urology 8

Optional Diagnostic Tests (Selective Use)

• Optional tests like uroflowmetry and post-void residual are not required for watchful waiting or initiating medical therapy, but may be considered when initial evaluation suggests non-prostatic cause of symptoms, patient selects invasive therapy, or results would change management, according to The Journal of Urology 8
• Uroflowmetry may predict surgical response, as men with Qmax <10 mL/sec are more likely to have urodynamic obstruction and improve with surgery, as reported by The Journal of Urology 8
• Post-Void Residual (PVR) Volume may indicate bladder dysfunction and predict slightly less favorable treatment response, with large PVR volumes (e.g., 350 mL) potentially heralding disease progression, as noted by The Journal of Urology 8

Common Pitfalls to Avoid

• Do not use symptom scores alone to determine need for intervention, as it is critical to assess how bothersome symptoms are to the individual patient, as recommended by The Journal of Urology 8
• Do not withhold treatment based solely on elevated PVR, as it is not a contraindication to conservative or medical management, according to The Journal of Urology 8
• Do not order uroflowmetry before starting alpha-blockers, as symptom response to alpha-blockers is not dependent on baseline flow rate, as reported by The Journal of Urology 8

Assessment of Benign Prostatic Hyperplasia

Diagnostic Evaluation

• The American Urological Association recommends that optional tests like uroflowmetry and post-void residual should be reserved for specific clinical scenarios, such as when initial evaluation suggests non-prostatic cause of symptoms, patient selects invasive therapy, or patient has complex medical history 9
• Men with maximum flow rate (Qmax) <10 mL/sec are more likely to have urodynamic obstruction and improve with surgery, according to The Journal of Urology 9
• Large post-void residual (PVR) volumes may indicate bladder dysfunction and predict slightly less favorable treatment response, potentially heralding disease progression, as noted in The Journal of Urology 9
• PVR is not a contraindication to watchful waiting or medical therapy, and many patients maintain large residual volumes without urinary tract infection, renal insufficiency, or bothersome symptoms, as stated in The Journal of Urology 9

Ultrasound Scoring for Benign Prostatic Hyperplasia (BPH)

Introduction to Ultrasound Assessment

• The American Urological Association recommends transabdominal ultrasound assessment of intravesical prostatic protrusion (IPP) grading combined with prostate volume and post-void residual for anatomical staging of BPH 10

Recommended Ultrasound Assessment Parameters

• Essential measurements to obtain when performing transabdominal ultrasound for BPH evaluation include prostate volume, post-void residual (PVR), IPP grade, and anatomical features such as presence of intravesical lobes that may impact therapy choice 10

Clinical Staging Based on Ultrasound Findings

• The European Association of Urology suggests that a practical staging system integrates ultrasound findings with symptoms, although the specific guideline is not mentioned in the article, the concept is supported by 10

When Ultrasound Is Indicated

• The American Urological Association indicates that transabdominal or transrectal ultrasound is appropriate when a patient has selected minimally invasive or surgical intervention, determining candidacy for specific procedures, or assessing for intravesical lobes that impact surgical approach 10
• Ultrasound is not necessary for initial evaluation before watchful waiting, starting medical therapy, or determining "need for treatment" as symptoms and bother drive this decision, according to the principles of the American Urological Association 10

Important Caveats

• Prostate size alone does not determine treatment need, as a man with a large prostate but minimal symptoms may not require intervention, while someone with moderate enlargement but severe bother may benefit from treatment, as suggested by the principles of urological management 11